TNF Pharmaceuticals, Inc.
TNFA
$0.22
$0.02814.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.80% | -42.09% | -58.96% | 50.00% | 45.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.41% | -52.49% | -67.81% | 52.37% | 28.90% |
| Operating Income | 55.41% | 52.49% | 67.81% | -52.37% | -28.90% |
| Income Before Tax | 12.66% | -147.72% | -129.52% | -548.28% | 36.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.66% | -147.72% | -129.52% | -548.28% | 36.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.66% | -147.72% | -129.52% | -548.28% | 36.89% |
| EBIT | 55.41% | 52.49% | 67.81% | -52.37% | -28.90% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 59.85% | -160.18% | -41.21% | -328.34% | 3.79% |
| Normalized Basic EPS | 45.42% | -131.24% | -42.36% | -321.89% | 53.48% |
| EPS Diluted | 59.90% | -400.00% | -41.21% | -328.34% | 3.67% |
| Normalized Diluted EPS | 45.42% | -256.12% | -42.36% | -321.89% | 53.48% |
| Average Basic Shares Outstanding | 59.66% | 54.39% | 61.28% | 53.79% | 35.75% |
| Average Diluted Shares Outstanding | 59.66% | -69.11% | 61.28% | 53.79% | 35.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.07% | -- | -- | -- | -- |